OxLDL Triggers Retrograde Translocation of Arginase2 in Aortic Endothelial Cells via ROCK and Mitochondrial Processing Peptidase

Circulation Research

Volumn 115, Issue 4, 2014, Pages 450-459

  Pandey, Deepesh ^a   Bhunia, Anil ^a   Oh, Young Jun ^a   Chang, Fumin ^a   Bergman, Yehudit ^a   Kim, Jae Hyung ^a   Serbo, Janna ^a   Boronina, Tatiana N ^a   Cole, Robert N ^a   Van Eyk, Jennifer ^a   Remaley, Alan T ^b   Berkowitz, Dan E ^a   Romer, Lewis H ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c JOHNS HOPKINS CHILDREN S CENTER   (United States)

Author keywords

arginase; atherosclerosis; mitochondria; mitochondrial processing peptidase; nitric oxide synthase type III; oxidized low density lipoprotein

Indexed keywords

ARGINASE; ARGINASE 2; LECTIN; MITOCHONDRIAL PROCESSING PEPTIDASE; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR; PEPTIDASE; PHOSPHOTRANSFERASE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; ARG2 PROTEIN, MOUSE; ARGINASE II, HUMAN; LOW DENSITY LIPOPROTEIN; METALLOPROTEINASE; OLR1 PROTEIN, MOUSE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PROTEIN KINASE INHIBITOR; RHO KINASE;

AMINO ACID SEQUENCE; ANIMAL TISSUE; AORTA; AORTA INTIMA; ARTICLE; CONTROLLED STUDY; CYTOSOL; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN TRANSPORT; SEQUENCE ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTIC DISEASES; ATHEROSCLEROSIS; C57BL MOUSE; CELL CULTURE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; MITOCHONDRION; MOLECULAR GENETICS; PATHOLOGY; PATHOPHYSIOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR; TRANSGENIC MOUSE;

AMINO ACID SEQUENCE; ANIMALS; AORTA; AORTIC DISEASES; APOLIPOPROTEINS E; ARGINASE; ATHEROSCLEROSIS; CELLS, CULTURED; CYTOSOL; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HUMANS; LIPOPROTEINS, LDL; MALE; METALLOENDOPEPTIDASES; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MITOCHONDRIA; MOLECULAR SEQUENCE DATA; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; RHO-ASSOCIATED KINASES; RNA INTERFERENCE; SCAVENGER RECEPTORS, CLASS E; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84905217813     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.304262     Document Type: Article

References (47)

1. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997;272:20963-20966.
2. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
4. Galle J, Bengen J, Schollmeyer P, Wanner C. Impairment of endotheliumdependent dilation in rabbit renal arteries by oxidized lipoprotein(a). Role of oxygen-derived radicals. Circulation. 1995;92:1582-1589.
5. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 1990;344:160-162.
6. Li H, Förstermann U. Prevention of atherosclerosis by interference with the vascular nitric oxide system. Curr Pharm Des. 2009;15:3133-3145.
7. Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S, Burke S, Shoukas AA, Nyhan D, Champion HC, Hare JM. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation. 2003;108:2000-2006.
8. Closs EI, Simon A, Vékony N, Rotmann A. Plasma membrane transporters for arginine. J Nutr. 2004;134:2752S-2759S; discussion 2765S.
9. Haraguchi Y, Takiguchi M, Amaya Y, Kawamoto S, Matsuda I, Mori M. Molecular cloning and nucleotide sequence of cDNA for human liver arginase. Proc Natl Acad Sci U S A. 1987;84:412-415.
10. Morris SM Jr, Bhamidipati D, Kepka-Lenhart D. Human type II arginase: sequence analysis and tissue-specific expression. Gene. 1997;193:157-161.
11. Chang CI, Liao JC, Kuo L. Arginase modulates nitric oxide production in activated macrophages. Am J Physiol. 1998;274:H342-H348.
12. Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, del Soldato P. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A. 2001;98:4202-4208.
13. Li H, Meininger CJ, Hawker JR Jr, Haynes TE, Kepka-Lenhart D, Mistry SK, Morris SM Jr, Wu G. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab. 2001;280:E75-E82.
14. Modolell M, Corraliza IM, Link F, Soler G, Eichmann K. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur J Immunol. 1995;25:1101-1104.
15. Morris SM Jr, Kepka-Lenhart D, Chen LC. Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. Am J Physiol. 1998;275:E740-E747.
16. Louis CA, Reichner JS, Henry WL Jr, Mastrofrancesco B, Gotoh T, Mori M, Albina JE. Distinct arginase isoforms expressed in primary and transformed macrophages: regulation by oxygen tension. Am J Physiol. 1998;274:R775-R782.
17. Collado B, Sánchez-Chapado M, Prieto JC, Carmena MJ. Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells. Mol Cell Endocrinol. 2006;249:116-122.
18. Hein TW, Zhang C, Wang W, Chang CI, Thengchaisri N, Kuo L. Ischemiareperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J. 2003;17:2328-2330.
19. Jung C, Gonon AT, Sjöquist PO, Lundberg JO, Pernow J. Arginase inhibition mediates cardioprotection during ischaemia-reperfusion. Cardiovasc Res. 2010;85:147-154.
20. Zhang C, Hein TW, Wang W, Miller MW, Fossum TW, McDonald MM, Humphrey JD, Kuo L. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension. 2004;44:935-943.
21. Johnson FK, Johnson RA, Peyton KJ, Durante W. Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol. 2005;288:R1057-R1062.
22. Peyton KJ, Ensenat D, Azam MA, Keswani AN, Kannan S, Liu XM, Wang H, Tulis DA, Durante W. Arginase promotes neointima formation in rat injured carotid arteries. Arterioscler Thromb Vasc Biol. 2009;29:488-494.
23. Ryoo S, Gupta G, Benjo A, et al. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res. 2008;102:923-932.
24. Ryoo S, Lemmon CA, Soucy KG, Gupta G, White AR, Nyhan D, Shoukas A, Romer LH, Berkowitz DE. Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ Res. 2006;99:951-960.
25. Ming XF, Barandier C, Viswambharan H, Kwak BR, Mach F, Mazzolai L, Hayoz D, Ruffieux J, Rusconi S, Montani JP, Yang Z. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation. 2004;110:3708-3714.
26. Ryoo S, Bhunia A, Chang F, Shoukas A, Berkowitz DE, Romer LH. OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling. Atherosclerosis. 2011;214:279-287.
27. Levillain O, Balvay S, Peyrol S. Mitochondrial expression of arginase II in male and female rat inner medullary collecting ducts. J Histochem Cytochem. 2005;53:533-541.
28. Lim HK, Lim HK, Ryoo S, Benjo A, Shuleri K, Miriel V, Baraban E, Camara A, Soucy K, Nyhan D, Shoukas A, Berkowitz DE. Mitochondrial arginase II constrains endothelial NOS-3 activity. Am J Physiol Heart Circ Physiol. 2007;293:H3317-H3324.
29. Lucas R, Czikora I, Sridhar S, Zemskov EA, Oseghale A, Circo S, Cederbaum SD, Chakraborty T, Fulton DJ, Caldwell RW, Romero MJ. Arginase 1: an unexpected mediator of pulmonary capillary barrier dysfunction in models of acute lung injury. Front Immunol. 2013;4:228.
30. Kubli DA, Gustafsson ÅB. Mitochondria and mitophagy: the yin and yang of cell death control. Circ Res. 2012;111:1208-1221.
31. Li M, Zhong Z, Zhu J, Xiang D, Dai N, Cao X, Qing Y, Yang Z, Xie J, Li Z, Baugh L, Wang G, Wang D. Identification and characterization of mitochondrial targeting sequence of human apurinic/apyrimidinic endonuclease 1. J Biol Chem. 2010;285:14871-14881.
32. Niidome T, Kitada S, Shimokata K, Ogishima T, Ito A. Arginine residues in the extension peptide are required for cleavage of a precursor by mitochondrial processing peptidase. Demonstration using synthetic peptide as a substrate. J Biol Chem. 1994;269:24719-24722.
33. Vaisman BL, Andrews KL, Khong SM, Wood KC, Moore XL, Fu Y, Kepka- Lenhart DM, Morris SM Jr, Remaley AT, Chin-Dusting JP. Selective endothelial overexpression of arginase II induces endothelial dysfunction and hypertension and enhances atherosclerosis in mice. PLoS One. 2012;7:e39487.
34. Fleming I, Mohamed A, Galle J, Turchanowa L, Brandes RP, Fisslthaler B, Busse R. Oxidized low-density lipoprotein increases superoxide production by endothelial nitric oxide synthase by inhibiting PKCalpha. Cardiovasc Res. 2005;65:897-906.
35. Khong SM, Andrews KL, Huynh NN, Venardos K, Aprico A, Michell DL, Zarei M, Moe KT, Dusting GJ, Kaye DM, Chin-Dusting JP. Arginase II inhibition prevents nitrate tolerance. Br J Pharmacol. 2012;166:2015-2023.
36. Kim JH, Bugaj LJ, Oh YJ, et al. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J Appl Physiol (1985). 2009;107:1249-1257.
37. Greene AW, Grenier K, Aguileta MA, Muise S, Farazifard R, Haque ME, McBride HM, Park DS, Fon EA. Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment. EMBO Rep. 2012;13:378-385.
38. Schmidt O, Pfanner N, Meisinger C. Mitochondrial protein import: from proteomics to functional mechanisms. Nat Rev Mol Cell Biol. 2010;11:655-667.
39. Neupert W, Herrmann JM. Translocation of proteins into mitochondria. Annu Rev Biochem. 2007;76:723-749.
40. Stein I, Peleg Y, Even-Ram S, Pines O. The single translation product of the FUM1 gene (fumarase) is processed in mitochondria before being distributed between the cytosol and mitochondria in Saccharomyces cerevisiae. Mol Cell Biol. 1994;14:4770-4778.
41. Dinur-Mills M, Tal M, Pines O. Dual targeted mitochondrial proteins are characterized by lower MTS parameters and total net charge. PLoS One. 2008;3:e2161.
42. Regev-Rudzki N, Yogev O, Pines O. The mitochondrial targeting sequence tilts the balance between mitochondrial and cytosolic dual localization. J Cell Sci. 2008;121:2423-2431.
43. Teixeira PF, Glaser E. Processing peptidases in mitochondria and chloroplasts. Biochim Biophys Acta. 2013;1833:360-370.
44. Grundtman C, Kreutmayer SB, Almanzar G, Wick MC, Wick G. Heat shock protein 60 and immune inflammatory responses in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:960-968.
45. Kurz S, Harrison DG. Insulin and the arginine paradox. J Clin Invest. 1997;99:369-370.
46. Erez A, Nagamani SC, Shchelochkov OA, et al. Requirement of argininosuccinate lyase for systemic nitric oxide production. Nat Med. 2011;17:1619-1626.
47. Shimokawa H, Morishige K, Miyata K, Kandabashi T, Eto Y, Ikegaki I, Asano T, Kaibuchi K, Takeshita A. Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res. 2001;51:169-177.